From: Thymectomy for non-thymomatous myasthenia gravis: a propensity score matched study
Characteristics | Unmatched (n = 395) | Matched (n = 98) | ||||
---|---|---|---|---|---|---|
Thymectomy (n = 183) | Controls (n = 212) | Absolute standardized difference | Thymectomy (n = 49) | Controls (n = 49) | Absolute standardized difference | |
Age (mean ± SD) | 34.8 ± 14.1 | 63.7 ± 12.7* | 2.33† | 49.8 ± 14.3 | 50.1 ± 13.2 | 0.02 |
Females [n (%)] | 124(68) | 89(42)* | 2.03† | 25(51) | 27(50) | 0.08 |
Time to Dx (mean ± SD) | 14.8 ± 26.1 | 16.9 ± 31.8 | 0.55† | 17.8 ± 25.6 | 18.3 ± 27.3 | 0.02 |
MGFA class at diagnosis n [(%)] | ||||||
MGFA I | 16(9) | 31(15)* | 0.21† | 5(10) | 4(8) | 0.07 |
MGFA II | 57(31) | 81(38) | 0.15† | 21(43) | 23(47) | 0.08 |
MGFA III | 70(38) | 73(34) | 0.08 | 17(35) | 15(31) | 0.08 |
MGFA IV/V | 40(22) | 27(13)* | 0.22† | 6(12) | 7(14) | 0.05 |
Medications [n(%)] | ||||||
Prednisone | 130(71) | 166(78) | 0.16† | 35(71) | 33(67) | 0.09 |
Azathioprine | 109(60) | 118(56) | 0.08 | 30(61) | 31(63) | 0.04 |
Mycophenolate | 32(18) | 41(19) | 0.05 | 6(12) | 7(14) | 0.05 |
Other immunosupressants | 28(15) | 21(10) | 0.15 | 4(8) | 5(10) | 0.07 |
Follow-up (mean ± SD) | 118.9 ± 115.9 | 67.4 ± 52.8* | 0.44† | 95.9 ± 103.1 | 76.4 ± 54.6 | 0.16† |